
Biological Evaluation Dossier - ISO 10993:2025 (ANVISA, FDA and CE Mark)
Structuring the Biological Evaluation Dossier under ISO 10993:2025, with BEP, BER and a risk-based approach for ANVISA, FDA and CE Mark.
- Duration
- 16 hours
- Format
- Live online
- Certification
- Exemplar Global
About the course
A course integrating the updated requirements of the ISO 10993:2025 series with ANVISA, FDA and CE Mark regulatory expectations for structuring the Biological Evaluation Dossier, including the Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER), focusing on a risk-based approach and minimising unnecessary testing.
What you will learn
Module 01ISO 10993 series fundamentals
Principles of biological evaluation and recent updates.
Module 02Categorisation and evaluation plan
Contact type and duration, and defining the strategy.
Module 03Chemical and toxicological characterisation
Using chemical data to justify or reduce testing.
Module 04Cytotoxicity, sensitisation and irritation
The initial tests and how to interpret them.
Module 05Systemic toxicity, genotoxicity and haemocompatibility
When these endpoints apply.
Module 06Implantation and degradation
Evaluation of prolonged-contact devices and absorbable materials.
Module 07Biological evaluation plan and report
Structure of the BEP and the BER.
Module 08Regulatory requirements
ANVISA, FDA and CE marking expectations.
Learning objective
Equip participants to plan, document and defend medical device biological evaluation before regulatory authorities, applying the risk-based approach of ISO 10993-1:2025 and building a robust dossier recognised in major global markets.
Who this course is for
R&D, Regulatory Affairs and Quality professionals, toxicologists, biomedical engineers and consultants involved in medical device biocompatibility evaluation.
Your instructor

Drª. Juliane Rossato
Dr Juliane Rossato, PhD Biomedical scientist with a PhD in clinical and regulatory evaluation of medical devices. More than 15 years in clinical research and ANVISA submissions. Co-inventor of an international patent. Biomedical scientist with a PhD in clinical and regulatory evaluation of medical devices More than 15 years in clinical and preclinical research Specialist in ANVISA submissions and projects involving stents, TAVI and nanotechnology Co-inventor of an international patent and leader of FINEP/TECNOVA-RS projects Expertise in ISO 14155:2020, MDR 2017/745 and RDC 848/2024 Clinical and biological evaluation Consultant and Instructor at HSC Global